Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is This Bidding War Almost Over?

By Dave Williamson - Apr 3, 2013 at 6:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this pharmaceutical finally close to being acquired?

The bidding war goes on to acquire Obagi Medical Products (NASDAQ: OMPI) and its dermatological product line, with the acquisitive Valeant Pharmaceuticals (BHC -2.67%) as the current top bidder at $24 per share. The ongoing bidding war has Obagi up another 10% today. Are we close to seeing a deal? In this video, Fool health-care analyst David Williamson tells investors how to play this buyout bidding race, both for current shareholders, and for those currently sitting on the sidelines.

Stocks Mentioned

Teva Pharmaceutical Industries Limited

TEVA

$8.45 (0.54%) $0.04

Bausch Health Companies Inc.

BHC

$10.73 (-2.67%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Moderna Just Made a $700,000 Mistake

Is Ocugen Finally on the Way to Vaccine Revenue?

Could Novavax's Next Step Make It a Multibagger?

These 3 Former High-Flying Stocks Can Soar Up to 439%, According to Wall Street

Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday

Motley Fool Returns

Market-beating stocks from our award-winning service.

Stock Advisor Returns

349%

S&P 500 Returns

122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.